伴有鸡蛋不耐受的皮肤过敏症患者接种灭活SARS-CoV-2疫苗的安全性调查（英文）
PDF下载 (164)江欣雨,赵可喻,刘志方,马艺钊,周琼艳,许素玲.伴有鸡蛋不耐受的皮肤过敏症患者接种灭活SARS-CoV-2疫苗的安全性调查（英文）[J].宁波大学学报(理工版),2023,36(1):65-74.DOI:
JIANG Xinyu,ZHAO Keyu,LIU Zhifang,MA Yizhao,ZHOU Qiongyan,XU Suling.Safe administration of inactivated SARS-CoV-2 vaccines in egg-intolerant adults with skin allergies[J].Journal of Ningbo University(Natural Science & Engineering Edition),2023,36(1):65-74.DOI:
| Title: | Safe administration of inactivated SARS-CoV-2 vaccines in egg-intolerant adults with skin allergies |
| 作者: | 江欣雨, 赵可喻, 刘志方, 马艺钊, 周琼艳, 许素玲 |
| Author(s): | JIANG Xinyu, ZHAO Keyu, LIU Zhifang, MA Yizhao, ZHOU Qiongyan, XU Suling |
| 关键词: | 鸡蛋不耐受; 严重急性呼吸综合征冠状病毒2; 皮肤过敏; 疫苗; 不良反应 |
| Keywords: | egg intolerance; SARS-CoV-2; skin allergy; vaccines; adverse reactions |
| 分类号: | R373.9 |
| 文献标识码: | A |
| 摘要: | 为明确灭活新型冠状病毒疫苗在伴有鸡蛋不耐受皮肤过敏症患者中的安全性, 该回顾性研究纳入缺乏鸡蛋过敏实验证据但鸡蛋不耐受的皮肤过敏症成年患者. 通过电话随访记录每次接种疫苗后7天的不良反应, 研究共纳入122名受试者(平均年龄(30±9.47)岁). 和鸡蛋耐受的受试者相比, 鸡蛋不耐受者在接种疫苗后会出现更多的不良反应(39.78%/17.24%, P<0.05). 同时, 特异性鸡蛋不耐受抗体的滴度与接种疫苗后不良反应的风险成正比(趋势P=0.008). 其中, 注射部位异常疼痛和新发或原有皮疹恶化为最常见的不良反应, 且在第一针剂后出现的概率更高. 多元回归分析调整后发现, 鸡蛋不耐受会增加注射部位异常疼痛(P=0.044, aOR: 5.061, 95%CI: 1.047~24.457)及新发或原有皮疹恶化(P=0.041, aOR: 9.109, 95%CI: 1.098~75.563)的风险. 结果表明: 灭活新型冠状病毒肺炎疫苗的总体安全性较高, 但鸡蛋不耐受会增加皮肤过敏患者接受疫苗后出现不良反应的风险, 并且与特异性鸡蛋不耐受抗体的血清浓度成正比. |
| Abstract: | The current study is to determine the safety of inactivated severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) vaccines in patients with skin allergies and egg intolerance but lacking laboratory evidence of egg allergy. This retrospective study included adults with skin allergies but lacking laboratory evidence of egg allergy who received two doses of the SARS-CoV-2 vaccines. Local and systemic reactions for 7 days following each vaccine dose were recorded during telephone interviews. 122 participants with skin allergies (mean age, 30±9.47 years) were enrolled. Egg-intolerant individuals had more anaphylactic reactions after receiving the vaccine than did egg-tolerant individuals (39.78%vs.17.24%, P<0.05). A higher titer of egg sIgG4 was associated with the increased risk of allergic responses after receiving the vaccine (P for trend=0.008). Unusual pain and new or worsened skin rashes were common reactions, especially after the first dose. After adjustments, egg-intolerance was correlated with a higher risk of unusual pain (P=0.044, adjusted odds ratio (aOR): 5.061, 95% confidence interval (CI): 1.047–24.457) and new or worsened skin rashes (P=0.041, aOR: 9.109, 95%CI: 1.098–75.563) after the first injection. The results supported the overall safety of inactivated SAR-CoV-2 vaccines. Egg intolerance increased the risk of allergic reactions in adults with skin allergies but lacking laboratory evidence of egg allergy within 7 days of receiving the inactivated vaccine. These reactions were more frequent after the first dose and were positively associated with egg serum concentration. |
| 参考文献 /References: | [1] Pang K P, Pan L J, Guo H, et al. Case report: Associated ocular adverse reactions with inactivated COVID-19 vaccine in China[J]. Frontiers in Medicine, 2022, 8:823346. [2] Intapiboon P, Seepathomnarong P, Ongarj J, et al. Immunogenicity and safety of an intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population[J]. Vaccines, 2021, 9(12):1375-1381. [3] Laisuan W. COVID-19 Vaccine anaphylaxis: Current evidence and future approaches[J]. Frontiers in Allergy, 2021, 2:801322. [4] Desai A P, Desai A P, Loomis G J. Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration[J]. Vaccine, 2021, 39(32):4407-4409. [5] Muthukumar J, Selvasekaran P, Lokanadham M, et al. Food and food products associated with food allergy and food intolerance: An overview[J]. Food Research International, 2020, 138:109780. [6] Aalberse R C, Platts-Mills T A, Rispens T. The developmental history of IgE and IgG4 antibodies in relation to atopy, eosinophilic esophagitis, and the modified TH2 response[J]. Current Allergy and Asthma Reports, 2016, 16(6):45-52. [7] Myszkowska D, Zapala B, Bulanda M, et al. Non-IgE mediated hypersensitivity to food products or food intolerance-problems of appropriate diagnostics[J]. Medicina (Kaunas, Lithuania), 2021, 57(11):1245-1252. [8] Shakoor Z, AlFaifi A, AlAmro B, et al. Prevalence of IgG-mediated food intolerance among patients with allergic symptoms[J]. Annals of Saudi Medicine, 2016, 36(6):386-390. [9] Cao C, Qiu F, Lou C C, et al. Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases[J]. Respiratory Research, 2022, 23(1):133-141. [10] Polack F P, Thomas S J, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine [J]. Annals of Internal Medicine, 2020, 383(27):2603-2615. [11] Norquist J M, Khawaja S S, Kurian C, et al. Adaptation of a previously validated vaccination report card for use in adult vaccine clinical trials to align with the 2007 FDA toxicity grading scale guidance[J]. Human Vaccines & Immunotherapeutics, 2012, 8(9):1208-1212. [12] Vander L T K, Chan E S, Connors L, et al. COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI)[J]. Allergy, Asthma, and Clinical Immunology: Official Journal of the Canadian Society of Allergy and Clinical Immunology, 2021, 17(1):29-38. [13] Li L, Robinson L B, Patel R, et al. Association of self-reported high-risk allergy history with allergy symptoms after COVID-19 vaccination[J]. JAMA Network Open, 2021, 4(10):e2131034. [14] Magen E L, Yakov A, Green I, et al. Chronic spontaneous urticaria after BNT162b2 mRNA (pfizer-BioNTech) vaccination against SARS-CoV-2[J]. Allergy and Asthma Proceeding, 2022, 43(1):30-36. [15] Rojas P E P, Crespo Q J, Tornero M P, et al. Safety of new mRNA vaccines against COVID-19 in severely allergic patients[J]. Journal of Investigational Allergology & Clinical Immunology, 2021, 31(2):180-181. [16] Robinson L B, Arroyo A C, Faridi M K, et al. Trends in US hospitalizations for anaphylaxis among infants and toddlers: 2006 to 2015[J]. Annals of Allergy, Asthma & Immunology, 2021, 126(2):168-174. [17] Liotti L, Bianchi A, Bottau P, et al. COVID-19 vaccines in children with cow’s milk and food allergies[J]. Nutrients, 2021, 13(8):2637. [18] Shimabukuro T. Allergic reactions including anaphylaxis after receipt of the first dose of pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020[J]. MMWR Morbidity and Mortality Weekly Report, 2021, 70(2):46-51. [19] Karakula-Juchnowicz H, Ga??cka M, Rog J, et al. The food-specific serum IgG reactivity in major depressive disorder patients, irritable bowel syndrome patients and healthy controls[J]. Nutrients, 2018, 10(5):548-556. [20] Wu M X, Wang X F, Sun L, et al. Associations between food-specific IgG and health outcomes in an asymptomatic physical examination cohort[J]. Nutrition & Metabolism, 2022, 19(1):22-29. [21] Shavit R, Maoz-Segal R, Iancovici-Kidon M, et al. Prevalence of allergic reactions after Pfizer-BioNTech COVID-19 vaccination among adults with high allergy risk[J]. JAMA Network Open, 2021, 4(8):e2122255. [22] Zafar M, Ewnetu B, Ahmed S, et al. COVID-19 vaccination-induced rash: Does the choice of vaccine matter?[J]. Cureus, 2021, 13(6):e15490. [23] Krantz M S, Kwah J H, Stone C A, et al. Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose[J]. JAMA Internal Medicine, 2021, 181(11):1530-1533. [24] Dreskin S C, Halsey N A, Kelso J M, et al. International consensus (ICON): Allergic reactions to vaccines[J]. World Allergy Organization Journal, 2016, 9(1):32. [25] Puig-Barberà J, Tamames-Gómez S, Plans-Rubio P, et al. Relative effectiveness of cell-cultured versus egg-based seasonal influenza vaccines in preventing influenza- related outcomes in subjects 18 years old or older: A systematic review and meta-analysis[J]. International Journal of Environmental Research and Public Health, 2022, 19(2):818-826. [26] Klimek L, Wicht-Langhammer S, von Bernus L, et al. Anaphylactic reactions to vaccines: Chicken egg allergy and the influenza H1N1 vaccination[J]. HNO, 2017, 65(10):834-839. [27] Tozandehjani S, Nasiri Kalmarzi R, Khodabandehloo M, et al. Safety of inactivated influenza vaccine in patients with egg allergy in Kurdistan Province, Iran[J]. Iranian Journal of Public Health, 2019, 48(4):758-763. [28] Leech S C, Ewan P W, Skypala I J, et al. BSACI 2021 guideline for the management of egg allergy[J]. Clinical & Experimental Allergy, 2021, 51(10):1262-1278. [29] Turner P J, Ansotegui I J, Campbell D E, et al. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee[J]. World Allergy Organization Journal, 2021, 14(2):100517. [30] Blumenthal K G, Freeman E E, Saff R R, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2[J]. The New England Journal of Medicine, 2021, 384(13):1273-1277. [31] Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal[J]. International Archives of Allergy and Immunology, 2012, 157(3):215-225. [32] Kanduc D, Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: Implications for the vaccine[J]. Immunologic Research, 2020, 68(5):310-313. [33] Magro C, Nuovo G, Mulvey J, et al. The skin as a critical window in unveiling the pathophysiologic principles of COVID-19[J]. Clinics in Dermatology, 2021, 39(6):934- 965. |
| 备注/Memo: | 收稿日期: 2022－10－27. 宁波大学学报（理工版）网址: http://journallg.nbu.edu.cn/基金项目: 浙江省医药卫生重大科技计划项目（WKJ-ZJ-2012）; 宁波市公益性计划项目（2022S065）; 宁波市医学重点学科建设项目（2022-F23）.第一作者: 江欣雨（1997－）, 女, 浙江宁波人, 在读硕士研究生, 主要研究方向: 过敏性疾病. E-mail: jiangliu0319@163.com*通信作者: 许素玲（1966－）, 女, 浙江义乌人, 教授, 主要研究方向: 皮肤恶性肿瘤、过敏性疾病. E-mail: xusuling@nbu.edu.cn 宁波大学学报（理工版）网址：http://journallg.nbu.edu.cn/ |
